Gastroenterologie
a hepatologie

Towards personalized treatment of alveolar echinococcosis: a pilot study measuring levels of albendazole-sulfoxide in a cohort of patients in Slovakia

Robert Rosoľanka ^{Orcid.org  1}, Martin Kertys², Nela Žideková³, Daniela Antolová⁴, Katarína Šimeková¹, Martin Súčik¹, Lenka Nosáková⁵, Lukáš Špaňo¹, Peter Bánovčin Jr⁶

+ Affiliation
¹ Klinika infektológie a cestovnej medicíny, JLF UK a UN Martin, Slovenská republika
² Ústav farmakológie JLF UK a UN Martin
³ Martinské centrum pre bio­medicínu, JLF UK a UN Martin
⁴ Parazitologický ústav, Slovenská akadémia vied, Košice, Slovenská republika
⁵ Interná klinika gastroenterologická JLF UK a UN Martin
⁶ Interná klinika gastroenterologická JLF UK a UN Martin, Slovenská republika

Summary

Introduction: Albendazole is still considered a cornerstone in the treatment of alveolar echinococcosis (AE). Its parasitostatic effect, together with variable individual plasma concentration, can be considered a therapeutic problem. For this reason, the measurement of the plasma concentration of its active metabolite, albendazole sulfoxide is important in optimizing treatment and minimizing toxicity. Aim: The aim of the study is to present preliminary data from Slovakia and to demonstrate the feasibility and applicability of albendazole sulfoxide (ASOX) levels in clinical practice. Methods: Determination of plasma concentrations of ASOX was performed in 19 patients with confirmed AE. The data were evaluated through a basic statistical analysis. A literature review supporting the applicability of monitoring therapeutic levels of ASOX (TDM) was carried out. Results: ASOX concentrations ranged from 1.18 to 12.10 μmol/ l (mean 4.11 μmol/ l), with some values exceeding the recommended therapeutic interval. Conclusion: Our conclusions confirm the technical and clinical feasibility of implementing TDM for ASOX and reflect the step towards personalized AE treatment in Slovakia

Keywords

alveolar echinococcosis, albendazol, albendazole-sulfoxide, TDM

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Brunetti E, Kern P, Vuitton DA. Expert consensus for the dia­gnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010; 114(1): 1– 16. doi: 10.1016/ j. actatropica.2009.11.001.
2. Oksanen A, Siles-Lucas M, Karamon J et al. The geographical distribution and prevalence of Echinococcus multilocularis in animals in the European Union and adjacent countries: a systematic review and meta-analysis. Parasit Vectors 2016; 9(1): 519. doi: 10.1186/ s13071-016-1746-4.
3. Hemphill A, Stadelmann B, Rufener R et al. Treatment of echinococcosis: albendazole and mebendazole –  what else? Parasite 2014; 21: 70. doi: 10.1051/ parasite/ 2014073.
4. Bardonnet K, Vuitton DA, Grenouillet F et al. 30-year course and favorable outcome of alveolar echinococcosis despite multiple metastatic organ involvement in a non-immune suppressed patient. Ann Clin Microbio­l Antimicrob 2013; 12: 1 doi: 10.1186/ 1476-0711-12-1.
5. Autier B, Dion S, Millon L. Chemotherapy for the treatment of alveolar echinococcosis: where are we? Parasite 2024; 31: 56. doi: 10.1051/ parasite/ 2024055.
6. Schulz JD, Neodo A, Coulibaly JT et al. Pharmacokinetics of albendazole, albendazole sulfoxide, and albendazole sulfone determined from plasma, blood, dried-blood spots, and Mitra samples of hookworm-infected adolescents. Antimicrob Agents Chemother 2019; 63(4): e02489-18. doi: 10.1128/ AAC.02489-18.
7. Steiger U, Cotting J, Reichen J.  Albendazole treatment of echinococcosis in humans: effects on microsomal metabolism and drug tolerance. Clin Pharmacol Ther 1990; 47(3): 347– 353. doi: 10.1038/ clpt.1990.38.
8. Reuter S, Jensen B, Buttenschoen K et al. Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J Antimicrob Chemother 2000; 46(3): 451– 456. doi: 10.1093/ jac/ 46.3.451.
9. Plum PE, Ausselet N, Kidd F et al. EchiNam: multicenter retrospective study on the experience, challenges, and pitfalls in the dia­gnosis and treatment of alveolar echinococcosis in Belgium. Eur J Clin Microbio­l Infect Dis 2025; 44(2): 263– 275. doi: 10.1007/ s10096-024-04996-4.
10. Chauchet A, Grenouillet F, Knapp J et al. Increased incidence and characteristics of alveolar echinococcosis in patients with immunosuppression-associated conditions. Clin Infect Dis 2014; 59(8): 1095– 1104. doi: 10.1093/ cid/ ciu520.
11. Alberta Precision Laboratories. Albendazole level monitoring in treatment of AE. 2022 [online]. Dostupné z: chrome-extension:/ / efaidnbmnnnibpcajpcglclefindmkaj/ https:/ / www.albertahealthservices.ca/ assets/ wf/ lab/ if-lab-hp-bulletin-albendazole-level-monitoring-in-treatment-of-ae-alveolar-echinococcosis.pdf.
12. Bresson-Hadni S, Spahr L, Chappuis F. Hepatic alveolar echinococcosis. Semin Liver Dis 2021; 41(4): 387– 408. doi: 10.1055/ s-0041-1730925.
13. Bresson-Hadni S, Montange D, Richou C et al. Tobacco, cannabis, and liquorice: hidden players altering albendazole metabolism in patients with hepatic alveolar echinococcosis. J Hepatol 2021; 74(2): 469– 471. doi: 10.1016/ j. jhep.2020. 10.032.
14. Lötsch F, Naderer J, Skuhala T et al. Intra-cystic concentrations of albendazole-sulphoxide in human cystic echinococcosis: a systematic review and analysis of individual patient data. Parasitol Res 2016; 115(8): 2995– 3001. doi: 10.1007/ s00436-016-5054-x.
15. Xu X, Qian X, Gao C et al. Advances in the pharmacological treatment of hepatic alveolar echinococcosis: from laboratory to clinic. Front Microbio­l 2022; 13: 953846. doi: 10.3389/ fmicb.2022.953846.
16. Ingold K, Bigler P, Thormann W et al. Efficacies of albendazole sulfoxide and albendazole sulfone against in vitro-cultivated Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 1999; 43(5): 1052– 1061. doi: 10.1128/ AAC.43.5.1052.
17. Hemphill A, Spicher M, Stadelmann B et al. Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis. Parasitology 2007; 134(13): 1657– 1670. doi: 10.1017/ S0031182007003198.